Drug intelligence / Profile preview

EP005

Development stage: Preclinical
Lead developer: Endpoint Health
Administration: Topical

Overview

EP005 is a drug candidate developed by Endpoint Health, Inc. It is currently in preclinical development and functions as a tissue factor modulator. The primary active indication identified for EP005 is inflammation, with potential applications in other diseases.

Targets

F3 (Tissue factor)

Beyond the preview

Go deeper on EP005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP005.

Explore the full profile